中度主动脉瓣狭窄对射血分数降低心衰患者的影响
本研究回顾性纳入9133例射血分数降低心衰(HFrEF)患者,比较无、中度及重度主动脉瓣狭窄(AS)的临床结局。中位随访3.1年,中度AS患者主要终点(全因死亡与心衰住院复合)发生率62.7%,显著高于无AS的45.9%;倾向评分匹配后中度AS与心衰住院和死亡风险增加相关(HR 1.24,95%CI 1.04-1.49,P=0.01)。主动脉瓣置换与生存改善相关(HR 0.60,95%CI 0.36-0.99,P<0.05)。
要点
- HFrEF合并中度AS患者主要终点发生率显著高于无AS者。
- 匹配后中度AS与心衰住院和死亡风险增加独立相关。
- 主动脉瓣置换与HFrEF合并AS患者生存改善相关。
核心结论
- 在HFrEF患者中,中度AS与心衰住院和死亡率增加相关。
- 需进一步研究明确该人群行主动脉瓣置换能否改善临床结局。
研究设计与样本
- 回顾性识别LVEF<50%且无、中度或重度AS的HFrEF患者,共纳入9133例,其中中度AS 374例、重度AS 362例。
- 主要终点为全因死亡与心衰住院的复合终点,比较各组及倾向评分匹配队列内的差异。
主要发现
- 中位随访3.1年,中度AS患者主要终点发生率为62.7%,无AS为45.9%(P<0.0001)。
- 重度AS与中度AS的主要终点发生率相似(62.0% vs 62.7%,P=0.68)。
- 重度AS患者心衰住院发生率低于中度AS(36.2% vs 43.6%,P<0.05),且随访期内更常接受AVR。
- 倾向评分匹配队列中,中度AS与心衰住院和死亡风险增加相关(HR 1.24,95%CI 1.04-1.49,P=0.01),且院外存活天数更少(P<0.0001)。
- AVR与生存改善相关(HR 0.60,95%CI 0.36-0.99,P<0.05)。
临床怎么用
- HFrEF患者合并中度AS应视为心衰住院和死亡高风险人群,需加强监测与管理。
- 对HFrEF合并中度AS患者,应考虑评估AVR的获益可能性,但需进一步研究支持。
局限性
- 本研究为回顾性设计,可能存在选择偏倚和未测量混杂。
- 中度AS和重度AS样本量较小(分别为374例和362例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Afterload from moderate aortic stenosis (AS) may contribute to adverse outcomes in patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: The authors evaluated clinical outcomes in patients with HFrEF and moderate AS relative to those without AS and with severe AS. METHODS: Patients with HFrEF, defined by left ventricular ejection fraction (LVEF) <50% and no, moderate, or severe AS were retrospectively identified. The primary endpoint, defined as a composite of all-cause mortality and heart failure (HF) hospitalization, was compared across groups and within a propensity score-matched cohort. RESULTS: We included 9,133 patients with HFrEF, of whom 374 and 362 had moderate and severe AS, respectively. Over a median follow-up time of 3.1 years, the primary outcome occurred in 62.7% of patients with moderate AS vs 45.9% with no AS (P < 0.0001); rates were similar with severe and moderate AS (62.0% vs 62.7%; P = 0.68). Patients with severe AS had a lower incidence of HF hospitalization (36.2% vs 43.6%; P < 0.05) and were more likely to undergo AVR within the follow-up period. Within a propensity score-matched cohort, moderate AS was associated with an increased risk of HF hospitalization and mortality (HR: 1.24; 95% CI: 1.04-1.49; P = 0.01) and fewer days alive outside of the hospital (P < 0.0001). Aortic valve replacement (AVR) was associated with improved survival (HR: 0.60; CI: 0.36-0.99; P < 0.05). CONCLUSIONS: In patients with HFrEF, moderate AS is associated with increased rates of HF hospitalization and mortality. Further investigation is warranted to determine whether AVR in this population improves clinical outcomes.
引用
- Khan, Khan, Chen, et al. Impact of Moderate Aortic Stenosis in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2023. PMID: 36990542. doi:10.1016/j.jacc.2023.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。